v3.26.1
Note 13 - Revenue Recognition (Details Textual) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Sep. 30, 2024
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Disaggregation of Revenue [Line Items]            
Accrued Expense, Payor Overpayment Reimbursement, Liability   $ 1,800   $ 1,800   $ 2,100
Contract with Customer, Performance Obligation Satisfied in Previous Period       100 $ 700  
Total revenues   163,580 $ 156,807 287,777 306,759  
BARDA Agreement [Member]            
Disaggregation of Revenue [Line Items]            
Total revenues $ 24,100     9,000 13,500  
Rayaldee [Member]            
Disaggregation of Revenue [Line Items]            
Contract with Customer, Liability, Revenue Recognized   8,100 7,200 14,400 13,500  
Total revenues   14,262 14,528 27,066 27,638  
Intellectual Property and Other [Member]            
Disaggregation of Revenue [Line Items]            
Total revenues   46,100 15,000 60,100 27,200  
Increase (Decrease), Revenue from Contract with Customer, Excluding Assessed Tax   31,100 15,000 32,800 27,200  
Intellectual Property and Other [Member] | BARDA Agreement [Member]            
Disaggregation of Revenue [Line Items]            
Total revenues   5,000 6,500 9,000 13,500  
Intellectual Property and Other [Member] | Nicoya            
Disaggregation of Revenue [Line Items]            
Total revenues   29,400   29,400    
Royalty [Member] | NGENLA            
Disaggregation of Revenue [Line Items]            
Total revenues   6,400 6,100 12,800 10,600  
Royalty [Member] | Eli Lilly and Regeneron            
Disaggregation of Revenue [Line Items]            
Total revenues   4,300   6,600    
Transfer of Intellectual Property and Other [Member]            
Disaggregation of Revenue [Line Items]            
Total revenues   $ 46,090 $ 14,963 $ 60,058 $ 27,229